Forward

Restructure Information

In May 2023, the U.S. Court of Appeals for the Second Circuit ruled in favor of Purdue Pharma’s Chapter 11 Plan of Reorganization (the “Plan”), affirming the Bankruptcy Court’s September 2021 confirmation order and holding that the Plan is appropriate under the law. The case was heard before the Supreme Court of the United States in December 2023. The Company’s Plan will deliver billions of dollars of value for victim compensation, opioid crisis abatement, and overdose rescue medicines. We continue to operate fully, honoring our existing relationships and meeting our obligations to our partners, customers, and consumers.

READ MORE HERE >

With a dedicated team and a robust pipeline of novel therapy candidates, we work to develop important new medicines that can meaningfully improve the lives of patients around the world.

About Us

Imbrium is a clinical-stage biopharmaceutical company dedicated to advancing medical science through the development of important new therapeutics.

Learn More

Pipeline

Our robust and diversified pipeline of investigational therapy candidates has been built to address many serious medical conditions.

Learn More

Collaboration

Imbrium is dedicated to collaborating with commercial and academic partners to advance novel therapies that address unmet patient need. We welcome the opportunity to learn about new drug development programs and technologies in the areas of CNS, oncology chemotherapeutics, and non-opioid pain. Please reach us at partnering@pharma.com .